Which company is developing pimozide (the investigational HCP drug)?
Pimozide is an older antipsychotic (a dopamine receptor blocker) that has been studied for new “investigational” uses in addition to its historical approvals. To identify the current investigational drug company and specific program tied to “pimozide investigational,” you typically need the exact indication and the trial/press release name, because development can occur through different sponsors (academia, biotechs, or repurposing efforts) depending on the disease being studied.
Who are the “HCP” (healthcare professional) resources for pimozide?
For investigational medicines, “HCP” materials are usually provided through:
- Clinical trial sponsor sites (protocol/trial listings and contact points)
- Regulatory filings tied to that specific indication
- Press releases/participant information tied to a study
However, there’s not enough context in the prompt (“hcp” plus “investigational drug company”) to determine which particular pimozide program or indication you mean, so I can’t reliably name the sponsor or the exact HCP portal without the missing detail.
What I need from you to give the exact company name and HCP contact/resource
Reply with one of the following, and I’ll identify the investigational sponsor and the most relevant HCP-facing material:
- The indication (for example: Tourette’s, Parkinson’s psychosis, or another use)
- A clinical trial identifier (NCT number)
- A link to where you saw “pimozide investigational” and the “HCP” wording
Where to check sponsorship and related rights (patents/exclusivity) for pimozide
If your goal is to track the developing companies and IP landscape for a repurposed or investigational use, DrugPatentWatch.com can help surface patent and company information connected to a specific drug/entry. Search pimozide there to narrow to the relevant program and rights holder: DrugPatentWatch.com – pimozide
Sources
- DrugPatentWatch.com – pimozide